111, Inc. (NASDAQ:YI) Short Interest Up 94.1% in March

111, Inc. (NASDAQ:YI) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 6,600 shares, an increase of 94.1% from the February 28th total of 3,400 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 40,600 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On 111

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its holdings in 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after buying an additional 305,339 shares during the last quarter. FIL Ltd purchased a new position in shares of 111 in the fourth quarter valued at about $450,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd purchased a new position in shares of 111 in the fourth quarter valued at about $245,000. Institutional investors own 21.32% of the company’s stock.

111 Stock Down 7.7 %

NASDAQ YI opened at $9.05 on Friday. The stock’s 50-day simple moving average is $7.76 and its two-hundred day simple moving average is $7.43. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The company has a market capitalization of $77.40 million, a price-to-earnings ratio of -2.26 and a beta of 0.46.

111 (NASDAQ:YI) last issued its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $527.14 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of 111 in a research report on Saturday, March 22nd.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.